{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T12:32:14Z","timestamp":1785069134826,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shenzhen Longgang Central Hospital Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute lymphoblastic leukemia (ALL) is a genetically heterogeneous malignancy often associated with poor prognosis due to chemotherapy resistance and relapse. Histone deacetylase (HDAC) inhibitors represent an emerging class of epigenetic antitumor drugs. Among them, HDAC6, which is an enzyme that deacetylates \u03b1-tubulin, is increasingly recognized as a potential therapeutic target in hematologic malignancies. The adhesion molecule very late antigen 4 (VLA-4) plays a key role in cell adhesion-mediated drug resistance (CAMDR). We hypothesized that inhibiting HDAC6 could counteract CAMDR mediated by crosstalk between \u03b1-tubulin and integrin signaling. This study therefore investigated the therapeutic potential of WT161, a selective HDAC6 inhibitor, focusing on its role in targeting of the VLA-4\/Focal adhesion kinase (FAK) signaling pathway in ALL. Human B-ALL (BALL-1, NALM6) and T-ALL (Jurkat, MOLT-4) cell lines were treated with WT161, and its effects on proliferation, adhesion, migration, apoptosis, and cell cycle progression were evaluated. Protein expression and phosphorylation were analyzed by Western blot, and VLA-4 expression was assessed using immunofluorescence. In vivo, NOD\/SCID mice xenografted with ALL cells were treated with WT161, vincristine, or their combination. WT161 significantly inhibited proliferation, reduced adhesion and migration, and induced apoptosis in ALL cells. Mechanistically, it decreased intracellular cAMP levels, thereby inhibiting Protein kinase A (PKA) activity and suppressing the FAK signaling pathway. In xenograft models, WT161 exhibited anti-tumor effects, which were enhanced in combination with vincristine. This study highlights WT161\u2019s therapeutic potential in ALL, demonstrating its ability to inhibit PKA activity and disrupt the VLA-4\/FAK pathway, thereby offering a promising novel strategy for ALL treatment.<\/jats:p>","DOI":"10.1038\/s41598-025-23887-y","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:12:55Z","timestamp":1763413975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective HDAC6 inhibitor WT161 modulates the VLA-4\/FAK pathway by inhibiting PKA activity in acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Chengfang","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"23887_CR1","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 7, e577 (2017).","journal-title":"Blood Cancer J."},{"key":"23887_CR2","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1021\/acs.biochem.0c00354","volume":"59","author":"A Radadiya","year":"2020","unstructured":"Radadiya, A., Zhu, W., Coricello, A., Alcaro, S. & Richards, N. G. J. Improving the treatment of acute lymphoblastic leukemia. Biochemistry 59, 3193\u20133200 (2020).","journal-title":"Biochemistry"},{"key":"23887_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang, L. N., Lee, S. H. R., Yang, J. J. & Schmiegelow, K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia 36, 1749\u20131758 (2022).","journal-title":"Leukemia"},{"key":"23887_CR4","doi-asserted-by":"crossref","unstructured":"Milazzo, G. et al. Histone deacetylases (HDACs): Evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes (Basel). 11 (2020).","DOI":"10.3390\/genes11050556"},{"key":"23887_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","volume":"30","author":"C Zhao","year":"2020","unstructured":"Zhao, C., Dong, H., Xu, Q. & Zhang, Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opin. Ther. Pat. 30, 263\u2013274 (2020).","journal-title":"Expert Opin. Ther. Pat."},{"key":"23887_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/17460441.2021.1877656","volume":"16","author":"M Su","year":"2021","unstructured":"Su, M., Gong, X. & Liu, F. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. Expert Opin. Drug Discov. 16, 745\u2013761 (2021).","journal-title":"Expert Opin. Drug Discov"},{"key":"23887_CR7","doi-asserted-by":"publisher","first-page":"105274","DOI":"10.1016\/j.phrs.2020.105274","volume":"163","author":"S Pulya","year":"2021","unstructured":"Pulya, S. et al. HDAC6 as privileged target in drug discovery: A perspective. Pharmacol. Res. 163, 105274 (2021).","journal-title":"Pharmacol. Res."},{"key":"23887_CR8","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1007\/s00018-015-2000-5","volume":"72","author":"L Li","year":"2015","unstructured":"Li, L. & Yang, X. J. Tubulin acetylation: responsible enzymes, biological functions and human diseases. Cell. Mol. Life Sci. 72, 4237\u20134255 (2015).","journal-title":"Cell. Mol. Life Sci."},{"key":"23887_CR9","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.2174\/0929867328666210902145102","volume":"29","author":"D Bonanni","year":"2022","unstructured":"Bonanni, D. et al. Dual targeting strategies on histone deacetylase 6 (HDAC6) and heat shock protein 90 (Hsp90). Curr. Med. Chem. 29, 1474\u20131502 (2022).","journal-title":"Curr. Med. Chem."},{"key":"23887_CR10","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/onc.2015.293","volume":"35","author":"Z Meng","year":"2016","unstructured":"Meng, Z., Jia, L. F. & Gan, Y. H. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Oncogene 35, 2333\u20132344 (2016).","journal-title":"Oncogene"},{"key":"23887_CR11","doi-asserted-by":"publisher","first-page":"80109","DOI":"10.18632\/oncotarget.19019","volume":"8","author":"T Hideshima","year":"2017","unstructured":"Hideshima, T. et al. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget 8, 80109\u201380123 (2017).","journal-title":"Oncotarget"},{"key":"23887_CR12","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.21037\/tcr.2019.10.30","volume":"8","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. HDAC6 inhibitor WT161 induces apoptosis in retinoblastoma cells and synergistically interacts with cisplatin. Transl Cancer Res. 8, 2759\u20132768 (2019).","journal-title":"Transl Cancer Res."},{"key":"23887_CR13","doi-asserted-by":"publisher","first-page":"13162","DOI":"10.1073\/pnas.1608067113","volume":"113","author":"T Hideshima","year":"2016","unstructured":"Hideshima, T. et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc. Natl. Acad. Sci. U S A. 113, 13162\u201313167 (2016).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"23887_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/med.10044","volume":"23","author":"GX Yang","year":"2003","unstructured":"Yang, G. X. & Hagmann, W. K. VLA-4 antagonists: potent inhibitors of lymphocyte migration. Med. Res. Rev. 23, 369\u2013392 (2003).","journal-title":"Med. Res. Rev."},{"key":"23887_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12185-010-0555-3","volume":"91","author":"Y Imai","year":"2010","unstructured":"Imai, Y., Shimaoka, M. & Kurokawa, M. Essential roles of VLA-4 in the hematopoietic system. Int. J. Hematol. 91, 569\u2013575 (2010).","journal-title":"Int. J. Hematol."},{"key":"23887_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12026-014-8527-y","volume":"59","author":"NM Chapman","year":"2014","unstructured":"Chapman, N. M. & Houtman, J. C. Functions of the FAK family kinases in T cells: beyond actin cytoskeletal rearrangement. Immunol. Res. 59, 23\u201334 (2014).","journal-title":"Immunol. Res."},{"key":"23887_CR17","doi-asserted-by":"publisher","first-page":"34845","DOI":"10.1074\/jbc.M304691200","volume":"278","author":"J Han","year":"2003","unstructured":"Han, J., Rose, D. M., Woodside, D. G., Goldfinger, L. E. & Ginsberg, M. H. Integrin alpha 4 beta 1-dependent T cell migration requires both phosphorylation and dephosphorylation of the alpha 4 cytoplasmic domain to regulate the reversible binding of paxillin. J. Biol. Chem. 278, 34845\u201334853 (2003).","journal-title":"J. Biol. Chem."},{"key":"23887_CR18","doi-asserted-by":"publisher","first-page":"17897","DOI":"10.1074\/jbc.M117.803775","volume":"292","author":"MK Yanda","year":"2017","unstructured":"Yanda, M. K., Liu, Q., Cebotaru, V., Guggino, W. B. & Cebotaru, L. Histone deacetylase 6 Inhibition reduces cysts by decreasing cAMP and Ca(2+) in knock-out mouse models of polycystic kidney disease. J. Biol. Chem. 292, 17897\u201317908 (2017).","journal-title":"J. Biol. Chem."},{"key":"23887_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbrc.2018.06.016","volume":"503","author":"S Jung","year":"2018","unstructured":"Jung, S. et al. HDAC6 regulates thermogenesis of brown adipocytes through activating PKA to induce UCP1 expression. Biochem. Biophys. Res. Commun. 503, 285\u2013290 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"23887_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","volume":"17","author":"P Gallinari","year":"2007","unstructured":"Gallinari, P. et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell. Res. 17, 195\u2013211 (2007).","journal-title":"Cell. Res."},{"key":"23887_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah, R. R. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 42, 235\u2013245 (2019).","journal-title":"Drug Saf."},{"key":"23887_CR22","doi-asserted-by":"publisher","first-page":"11558","DOI":"10.1111\/jcmm.15772","volume":"24","author":"T Liang","year":"2020","unstructured":"Liang, T. et al. HDAC6-mediated \u03b1-tubulin deacetylation suppresses autophagy and enhances motility of podocytes in diabetic nephropathy. J. Cell. Mol. Med. 24, 11558\u201311572 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"23887_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li, T. et al. Histone deacetylase 6 in cancer. J. Hematol. Oncol. 11, 111 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"23887_CR24","doi-asserted-by":"publisher","first-page":"BSR20203905","DOI":"10.1042\/BSR20203905","volume":"41","author":"J Sun","year":"2021","unstructured":"Sun, J. et al. HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU. Biosci. Rep. 41, BSR20203905 (2021).","journal-title":"Biosci. Rep."},{"key":"23887_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-022-02443-y","volume":"22","author":"B Yu","year":"2022","unstructured":"Yu, B. et al. The synergistic anticancer efect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma. Cancer Cell. Int. 22, 64 (2022).","journal-title":"Cancer Cell. Int."},{"key":"23887_CR26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","volume":"54","author":"L Marquard","year":"2009","unstructured":"Marquard, L. et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 54, 688\u2013698 (2009).","journal-title":"Histopathology"},{"key":"23887_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejphar.2018.03.026","volume":"828","author":"J Dong","year":"2018","unstructured":"Dong, J. et al. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer. Eur. J. Pharmacol. 828, 67\u201379 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"23887_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.devcel.2020.06.008","volume":"54","author":"A Roll-Mecak","year":"2020","unstructured":"Roll-Mecak, A. The tubulin code in microtubule dynamics and information encoding. Dev. Cell. 54, 7\u201320 (2020).","journal-title":"Dev. Cell."},{"key":"23887_CR29","doi-asserted-by":"publisher","first-page":"107552","DOI":"10.1016\/j.pharmthera.2020.107552","volume":"211","author":"M Barreca","year":"2020","unstructured":"Barreca, M., Stathis, A., Barraja, P. & Bertoni, F. An overview on anti-tubulin agents for the treatment of lymphoma patients. Pharmacol. Ther. 211, 107552 (2020).","journal-title":"Pharmacol. Ther."},{"key":"23887_CR30","doi-asserted-by":"publisher","first-page":"9075","DOI":"10.1038\/sj.onc.1207233","volume":"22","author":"KN Bhalla","year":"2003","unstructured":"Bhalla, K. N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22, 9075\u20139086 (2003).","journal-title":"Oncogene"},{"key":"23887_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbabio.2011.01.001","volume":"1807","author":"A Rovini","year":"2011","unstructured":"Rovini, A., Savry, A., Braguer, D. & Carre, M. Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochim. Biophys. Acta. 1807, 679\u2013688 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"23887_CR32","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","volume":"14","author":"MB Meads","year":"2008","unstructured":"Meads, M. B., Hazlehurst, L. A. & Dalton, W. S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14, 2519\u20132526 (2008).","journal-title":"Clin. Cancer Res."},{"key":"23887_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428199509064917","volume":"18","author":"KF Bradstock","year":"1995","unstructured":"Bradstock, K. F. & Gottlieb, D. J. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk. Lymphoma. 18, 1\u201316 (1995).","journal-title":"Leuk. Lymphoma"},{"key":"23887_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41580-021-00366-6","volume":"22","author":"S SenGupta","year":"2021","unstructured":"SenGupta, S., Parent, C. A. & Bear, J. E. The principles of directed cell migration. Nat. Rev. Mol. Cell. Biol. 22, 529\u2013547 (2021).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"23887_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-020-00191-1","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang, H., Kong, Q., Wang, J., Jiang, Y. & Hua, H. Complex roles of cAMP-PKA-CREB signaling in cancer. Exp. Hematol. Oncol. 9, 32 (2020).","journal-title":"Exp. Hematol. Oncol."},{"key":"23887_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1745-7270.2008.00438.x","volume":"40","author":"X Cheng","year":"2008","unstructured":"Cheng, X., Ji, Z., Tsalkova, T. & Mei, F. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim. Biophys. Sin (Shanghai). 40, 651\u2013662 (2008).","journal-title":"Acta Biochim. Biophys. Sin (Shanghai)"},{"key":"23887_CR37","doi-asserted-by":"crossref","unstructured":"Chan, G. K. L. et al. Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms. Elife 12 (2023).","DOI":"10.7554\/eLife.69521"},{"key":"23887_CR38","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1055\/s-0034-1384519","volume":"46","author":"PA Insel","year":"2014","unstructured":"Insel, P. A., Wilderman, A., Zhang, L., Keshwani, M. M. & Zambon, A. C. Cyclic AMP\/PKA-promoted apoptosis: insights from studies of S49 lymphoma cells. Horm. Metab. Res. 46, 854\u2013862 (2014).","journal-title":"Horm. Metab. Res."},{"key":"23887_CR39","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1471-4159.2007.04827.x","volume":"103","author":"C O\u2019Driscoll","year":"2007","unstructured":"O\u2019Driscoll, C., Wallace, D. & Cotter, T. G. bFGF promotes photoreceptor cell survival in vitro by PKA-mediated inactivation of glycogen synthase kinase 3beta and CREB-dependent Bcl-2 up-regulation. J. Neurochem. 103, 860\u2013870 (2007).","journal-title":"J. Neurochem"},{"key":"23887_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/ijmm.2025.5578","volume":"56","author":"F Qu","year":"2025","unstructured":"Qu, F., Zhao, Q. & Jin, Y. Histone deacetylase 6: A new player in oxidative stress-associated disorders and cancers (review). Int. J. Mol. Med. 56, 137 (2025).","journal-title":"Int. J. Mol. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23887-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:04:35Z","timestamp":1763805875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23887-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23887"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23887-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were approved by the Ethics Committee of Guangdong Medical Experimental Animal Center (Guangdong Province, China). All methods were carried out in accordance with relevant guidelines and regulations. All methods are reported in accordance with ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40178"}}